Key result
Aspirin cuts perinatal death ~21% and reduces preeclampsia in women with historical risk factors.
Why the study?
Does aspirin reduce perinatal death and preeclampsia in women with historical risk factors?
Meta-Analysis (n=12,416)
Does aspirin reduce perinatal death and preeclampsia in women with historical risk factors?
Odds Ratio: 0.79 (95% CI 0.64–0.96)
Aspirin therapy significantly reduces the risk of perinatal death and preeclampsia in women with historical risk factors, without increasing the risk of placental abruption.
Supports aspirin prophylaxis in women with historical risk factors; confirms perinatal death and preeclampsia reduction across 14 RCTs.
In Brief OBJECTIVE To examine the effectiveness of aspirin in preventing perinatal death and preeclampsia in women with predisposing historical risk factors, such as previous history of preeclampsia, chronic hypertension, diabetes, and renal disease. DATA SOURCES: Searches were conducted in MEDLINE, EMBASE, Cochrane Library, National Research Register, SCISEARCH, and ISI Conference Proceedings without any language restriction, using the following medical subject headings and text words: “aspirin,” “antiplatelet*,” “salicyl*,” “acetylsalicyl*,” “platelet aggregation inhibitors,” “pre-eclamp*,” “preeclamp*,” and “hypertens*.” METHODS OF STUDY SELECTION: We included all randomized trials that evaluated the effectiveness of aspirin compared with placebo or no treatment in women with predisposing historical risk factors and reported clinically relevant perinatal or maternal outcomes. Study selection, quality appraisal, and data extractions were performed independently and in duplicate. TABULATION, INTEGRATION, AND RESULTS: We identified 14 relevant trials, including a total of 12,416 women. Meta-analysis showed a significant benefit of aspirin therapy in reducing perinatal death (odds ratio [OR] 0.79, 95% confidence interval [CI] 0.64, 0.96) and preeclampsia (OR 0.86, 95% CI 0.76, 0.96). Aspirin was also associated with a reduction in rates of spontaneous preterm birth (OR 0.86, 95% CI 0.79, 0.94), and an increase of 215 g in mean birth weight (weighted mean difference 215, 95% CI 90, 341). There was no increase in the risk of placental abruption with aspirin (OR 0.98, 95% CI 0.79, 1.21). Funnel plot analysis indicated that publication and related biases were unlikely (Egger test, P = .84). CONCLUSION Aspirin reduces the risk of perinatal death and preeclampsia in women with historical risk factors. Given the importance of these outcomes and the safety and low cost of aspirin, aspirin therapy should be considered in women with historical risk factors. Assessment of historical risk factors (such as history of preeclampsia, chronic hypertension, and diabetes) identifies women in whom aspirin therapy reduces perinatal death and preeclampsia.
No takes yet. Share an insight, caveat, or question.
Coomarasamy et al. (2003) conducted a meta-analysis in Preeclampsia and perinatal death risk (n=12,416). Aspirin vs. Placebo or no treatment was evaluated on Perinatal death (OR 0.79, 95% CI 0.64, 0.96). Aspirin therapy significantly reduced the risk of perinatal death (OR 0.79; 95% CI 0.64-0.96) and preeclampsia (OR 0.86; 95% CI 0.76-0.96) in women with historical risk factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: